{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:00:50Z","timestamp":1785495650577,"version":"3.56.0"},"reference-count":33,"publisher":"Akademiai Kiado Zrt.","issue":"50","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EK\u00d6P","award":["2024-2.1.1-EK\u00d6P-2024-00004"],"award-info":[{"award-number":["2024-2.1.1-EK\u00d6P-2024-00004"]}]},{"name":"SE 250+ Kiv\u00e1l\u00f3s\u00e1gi PhD \u00d6szt\u00f6nd\u00edj"},{"DOI":"10.13039\/501100003549","name":"OTKA","doi-asserted-by":"crossref","award":["K-139139"],"award-info":[{"award-number":["K-139139"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"crossref"}]},{"name":"T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}]},{"name":"T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program","award":["TKP2021-NVA-15"],"award-info":[{"award-number":["TKP2021-NVA-15"]}]},{"name":"T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}]},{"name":"T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program","award":["01\/MGYH-MGYGYT\/2023"],"award-info":[{"award-number":["01\/MGYH-MGYGYT\/2023"]}]}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,12,14]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    A B-sejtes akut lymphoblastos leukaemia az egyik\n                    leggyakoribb gyermekkori malignit\u00e1s, m\u00edg feln\u0151ttkorban ritka betegs\u00e9gnek sz\u00e1m\u00edt.\n                    Gyermekkori betegpopul\u00e1ci\u00f3ban kor\u00e1bbi eredm\u00e9nyeink alapj\u00e1n a CD49f integrin a\n                    legt\u00f6bb esetben kifejez\u0151d\u00f6tt a lymphoblastokon, \u00e9s a diagn\u00f3ziskori intenz\u00edv\n                    expresszi\u00f3ja \u00f6sszef\u00fcgg\u00e9st mutatott az\n                    <jats:italic>ETV6::RUNX1<\/jats:italic>\n                    f\u00fazi\u00f3val.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    A feln\u0151ttkorban kialakul\u00f3 B-sejtes akut\n                    lymphoblastos leukaemi\u00e1t rosszabb progn\u00f3zis jellemzi, \u00edgy a betegs\u00e9g h\u00e1tter\u00e9nek\n                    \u00e9s mechanizmusainak felder\u00edt\u00e9se fontos feladat. C\u00e9lunk volt a CD49f-expresszi\u00f3\n                    meghat\u00e1roz\u00e1sa a diagn\u00f3ziskor \u00e9s a kezel\u00e9s alatt, valamint \u00f6sszevet\u00e9se a betegek\n                    genetikai h\u00e1tter\u00e9vel, klinikai adataival. Tov\u00e1bb\u00e1 tervezt\u00fck a CD49f-t\u0151l kiindul\u00f3\n                    jel\u00e1tviteli utak aktivit\u00e1s\u00e1nak meghat\u00e1roz\u00e1s\u00e1t.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A CD49f\n                    expresszi\u00f3j\u00e1t \u00f6sszehasonl\u00edtottuk \u00e1raml\u00e1si citometri\u00e1val B-sejtes akut\n                    lymphoblastos leukaemi\u00e1ban gyermek- (n = 84) \u00e9s feln\u0151tt- (n = 24)\n                    csontvel\u0151mint\u00e1kban, valamint az \u00e1ltala aktiv\u00e1lt jel\u00e1tviteli molekul\u00e1kat\n                    immunhisztok\u00e9mi\u00e1val csontbiopszi\u00e1kban (n = 10). \u00d6sszevetett\u00fck a klinikai \u00e9s a\n                    genetikai adatokat az expresszi\u00f3val.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    Diagnosztikus\n                    csontvel\u0151mint\u00e1ban gyermekek eset\u00e9n a mint\u00e1k 92%-\u00e1ban, a feln\u0151tt betegek\n                    mint\u00e1inak 75%-\u00e1ban volt kimutathat\u00f3 a CD49f. M\u00e9rhet\u0151 rezidu\u00e1lis betegs\u00e9ggel\n                    rendelkez\u0151 gyermekmint\u00e1kban szignifik\u00e1ns emelked\u00e9st tapasztaltunk a CD49f\n                    kifejez\u0151d\u00e9s\u00e9ben, feln\u0151ttekn\u00e9l nem v\u00e1ltozott. Gyermekekn\u00e9l a magas rizik\u00f3j\u00fa\n                    csoportba tartoz\u00f3 betegek diagn\u00f3ziskori CD49f-expresszi\u00f3-intenzit\u00e1sa nagyobb\n                    volt az alacsony rizik\u00f3j\u00fa csoporthoz k\u00e9pest, feln\u0151ttkorban ezzel ellent\u00e9tben a\n                    m\u00e9rhet\u0151 rezidu\u00e1lis betegs\u00e9gre n\u00e9zve pozit\u00edv betegekn\u00e9l kezdetben gyeng\u00e9bb\n                    expresszi\u00f3t figyelt\u00fcnk meg. A genetikai csoportokat tekintve jobb progn\u00f3zis\u00fa\n                    csoportok eset\u00e9n intenz\u00edvebb CD49f-expresszi\u00f3t, rossz progn\u00f3zis\u00fa elv\u00e1ltoz\u00e1sn\u00e1l\n                        (\n                    <jats:italic>KMT2A<\/jats:italic>\n                    g\u00e9n\u00e1trendez\u0151d\u00e9s) cs\u00f6kkent kifejez\u0151d\u00e9st mutattunk ki\n                    (P&lt;0,001). A jel\u00e1tviteli \u00fatvonalakat vizsg\u00e1lva, az intenz\u00edv CD49f-expresszi\u00f3\n                    fokozottabb Src- \u00e9s fok\u00e1lis adh\u00e9zi\u00f3s kin\u00e1z fest\u0151d\u00e9ssel t\u00e1rsult,\n                    \u2019integrin-linked\u2019 kin\u00e1z aktiv\u00e1ci\u00f3 nem volt megfigyelhet\u0151.\n                    <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic>\n                    A CD49f megb\u00edzhat\u00f3 m\u00e9rhet\u0151\n                    rezidu\u00e1lisbetegs\u00e9g-markernek bizonyult mindk\u00e9t popul\u00e1ci\u00f3ban. A diagnosztikus\n                    expresszi\u00f3nak a m\u00e9rhet\u0151 rezidu\u00e1lis betegs\u00e9ggel val\u00f3 kapcsolata ellent\u00e9tes;\n                    gyermekpopul\u00e1ci\u00f3ban az intenz\u00edvebb expresszi\u00f3 a blastok nagyobb ar\u00e1ny\u00e1val\n                    f\u00fcgg\u00f6tt \u00f6ssze, feln\u0151tt popul\u00e1ci\u00f3ban ennek ford\u00edtottja volt igaz. A genetikai\n                    csoportok \u00e9s a CD49f-intenzit\u00e1s\u00e9rt\u00e9kek k\u00f6z\u00f6tt hasonl\u00f3 \u00f6sszef\u00fcgg\u00e9seket tal\u00e1ltunk\n                    gyermek- \u00e9s feln\u0151tt betegpopul\u00e1ci\u00f3ban. A CD49f kifejez\u0151d\u00e9se a fok\u00e1lis adh\u00e9zi\u00f3s\n                    kin\u00e1z\u2013Src jel\u00fat aktivit\u00e1sfokoz\u00f3d\u00e1s\u00e1val mutatott \u00f6sszef\u00fcgg\u00e9st.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Eredm\u00e9nyeink alapj\u00e1n a CD49f-molekula j\u00f3l\n                    haszn\u00e1lhat\u00f3 m\u00e9rhet\u0151 rezidu\u00e1lisbetegs\u00e9g-marker gyermek- \u00e9s feln\u0151ttkori B-sejtes\n                    akut lymphoblastos leukaemi\u00e1s betegcsoportokn\u00e1l egyar\u00e1nt, expresszi\u00f3ja\n                    \u00f6sszef\u00fcgg\u00e9st mutat genetikai elt\u00e9r\u00e9sekkel, valamint a fok\u00e1lis adh\u00e9zi\u00f3s kin\u00e1z\u2013Src\n                    \u00fatvonal aktiv\u00e1l\u00f3d\u00e1s\u00e1val. Orv Hetil. 2025; 166(50): 1983\u20131992.\n                  <\/jats:p>","DOI":"10.1556\/650.2025.33419","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T14:34:53Z","timestamp":1765722893000},"page":"1983-1992","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A CD49f kifejez\u0151d\u00e9s\u00e9nek vizsg\u00e1lata gyermek- \u00e9s feln\u0151ttkori B-sejtes akut lymphoblastos leukaemi\u00e1ban"],"prefix":"10.1556","volume":"166","author":[{"given":"Anna","family":"Hunyadi","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"K\u0151szegi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Kriston","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Szal\u00f3ki","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajnalka","family":"Rajnai","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borb\u00e1la","family":"P\u00e9terffy","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bek\u0151","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"T\u00e1rk\u00e1nyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rakonczai","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Kovalovszki","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika, T\u0171zolt\u00f3 utcai R\u00e9szleg Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l Orsz\u00e1gos Gyermekgy\u00f3gy\u00e1szati Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Ma\u00e1r","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l Orsz\u00e1gos Gyermekgy\u00f3gy\u00e1szati Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel J\u00e1nos","family":"Erd\u00e9lyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika, T\u0171zolt\u00f3 utcai R\u00e9szleg Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Kutszegi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Gyermekgy\u00f3gy\u00e1szati Klinika, T\u0171zolt\u00f3 utcai R\u00e9szleg Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Barna","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-6507","authenticated-orcid":true,"given":"\u00c1gnes","family":"M\u00e1rk","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Kroeze E, Arias Padilla L, Bakker M, et al. Pediatric precursor\n                    B-cell lymphoblastic malignancies: From extramedullary to medullary involvement.\n                    Cancers 2022; 14: 3895.\n                    https:\/\/doi.org\/10.3390\/cancers14163895","DOI":"10.3390\/cancers14163895"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis\n                    in acute lymphoblastic leukemia. N Engl J Med. 2009; 360: 470-480.\n                        https:\/\/doi.org\/10.1056\/NEJMoa0808253","DOI":"10.1056\/NEJMc090454"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Sun C, Chang L, Zhu X. Pathogenesis of\n                    ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia and\n                    mechanisms underlying its relapse. Oncotarget 2017; 8: 35445-35459.\n                        https:\/\/doi.org\/10.18632\/oncotarget.16367","DOI":"10.18632\/oncotarget.16367"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"H\u00f3fer JH, K\u00e1rp\u00e1ti JM, Bedics G, et al. The role of molecular\n                    pathology in the diagnosis, prognosis, and management of childhood. [A\n                    molekul\u00e1ris patol\u00f3gia szerepe a gyermekkori tumorok diagnosztik\u00e1j\u00e1ban,\n                    prognosztik\u00e1j\u00e1ban \u00e9s kezel\u00e9s\u00e9ben.] Orv Hetil. 2025; 166: 1563-1573. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2025.33403","DOI":"10.1556\/650.2025.33403"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Passet M, Kim R, Clappier E. Genetic subtypes of B-cell acute\n                    lymphoblastic leukemia in adults. Blood 2025; 145: 1451-1463.\n                        https:\/\/doi.org\/10.1182\/blood.2023022919","DOI":"10.1182\/blood.2023022919"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"K\u00fcnz T, Hauswirth AW, Hetzenauer G, et al. Changing landscape in the\n                    treatment of adult acute lymphoblastic leukemia (ALL). Cancers 2022; 14: 4290.\n                        https:\/\/doi.org\/10.3390\/cancers14174290","DOI":"10.3390\/cancers14174290"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, et al. KMT2A\n                    rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int\n                    J Mol Sci 2024; 25: 9023.\n                    https:\/\/doi.org\/10.3390\/ijms25169023","DOI":"10.3390\/ijms25169023"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological\n                    implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.\n                        https:\/\/doi.org\/10.1038\/nrc2748","DOI":"10.1038\/nrc2748"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Krebsbach PH, Villa-Diaz LG. The role of integrin \u03b16 (CD49f) in stem\n                    cells: More than a conserved biomarker. Stem Cells Dev. 2017; 26: 1090-1099.\n                        https:\/\/doi.org\/10.1089\/scd.2016.0319","DOI":"10.1089\/scd.2016.0319"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Gang EJ, Kim HN, Hsieh YT, et al. Integrin \u03b16 mediates the drug\n                    resistance of acute lymphoblastic B-cell leukemia. Blood 2020; 1, 36: 210-223.\n                        https:\/\/doi.org\/10.1182\/blood.2019001417","DOI":"10.1182\/blood.2019001417"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Yao H, Price TT, Cantelli G, et al. Leukaemia hijacks a neural\n                    mechanism to invade the central nervous system. Nature 2018; 560: 55-60.\n                        https:\/\/doi.org\/10.1038\/s41586-018-0342-5","DOI":"10.1038\/s41586-018-0342-5"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in\n                    precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal\n                    residual disease detection. Cytometry B. Clin Cytom. 2009; 76: 150-155.\n                        https:\/\/doi.org\/10.1002\/cyto.b.20440","DOI":"10.1002\/cyto.b.20440"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Burridge K. Focal adhesions: a personal perspective on a half\n                    century of progress. FEBS J. 2017; 284: 3355-3361.\n                        https:\/\/doi.org\/10.1111\/febs.14195","DOI":"10.1111\/febs.14195"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Schlaepfer DD, Ojalill M, Stupack DG. Focal adhesion kinase\n                    signaling - tumor vulnerabilities and clinical opportunities. J Cell Sci. 2024;\n                    137: jcs261723. https:\/\/doi.org\/10.1242\/jcs.261723","DOI":"10.1242\/jcs.261723"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Raji L, Tetteh A, Amin AR. Role of c-Src in carcinogenesis and drug\n                    resistance. Cancers 2024; 16: 32.\n                        https:\/\/doi.org\/10.3390\/cancers16010032","DOI":"10.3390\/cancers16010032"},{"key":"R16","unstructured":"Zheng CC, Hu HF, Hong P, et al. Significance of integrin-linked\n                    kinase (ILK) in tumorigenesis and its potential implication as a biomarker and\n                    therapeutic target for human cancer. Am J Cancer Res. 2019; 9:\n                    186-197."},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Hunyadi A, Kriston C, Szal\u00f3ki G, et al. The significance of CD49f\n                    expression in pediatric B-cell acute lymphoblastic leukemia. Am J Clin Pathol.\n                    2025; 163: 169-177.\n                    https:\/\/doi.org\/10.1093\/ajcp\/aqae105","DOI":"10.1093\/ajcp\/aqae105"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow\n                    cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic\n                    leukemia. Blood 2017; 129: 347-357.\n                        https:\/\/doi.org\/10.1182\/blood-2016-07-726307","DOI":"10.1182\/blood-2016-07-726307"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Silva KA, Spagnol F, Farias MG, et al. Influence of minimal residual\n                    disease by multiparametric flow cytometry at day 15 of induction in risk\n                    stratification of children with B-cell acute lymphoblastic leukemia treated at a\n                    referral hospital in southern Brazil. Hematol Transfus Cell Ther. 2020; 42:\n                    348-355. https:\/\/doi.org\/10.1016\/j.htct.2019.10.002","DOI":"10.1016\/j.htct.2019.10.002"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Campbell M, Kiss C, Zimmermann M, et al. Childhood acute\n                    lymphoblastic leukemia: Results of the Randomized Acute Lymphoblastic Leukemia\n                    Intercontinental-Berlin-Frankfurt-M\u00fcnster 2009 Trial. J Clin Oncol. 2023; 41:\n                    3499-3511. https:\/\/doi.org\/10.1200\/JCO.22.01760","DOI":"10.1200\/JCO.22.01760"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Zawitkowska J, Lejman M, Romiszewski M, et al. Results of two\n                    consecutive treatment protocols in Polish children with acute lymphoblastic\n                    leukemia. Sci Rep. 2020; 10: 20168.\n                        https:\/\/doi.org\/10.1038\/s41598-020-75860-6","DOI":"10.1038\/s41598-020-75860-6"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Kruth KA, Fang M, Shelton DN, et al. Suppression of B-cell\n                    development genes is key to glucocorticoid efficacy in treatment of acute\n                    lymphoblastic leukemia. Blood 2017; 129: 3000-3008.\n                        https:\/\/doi.org\/10.1182\/blood-2017-02-766204","DOI":"10.1182\/blood-2017-02-766204"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Ryu JS, Majeska RJ, Ma Y, et al. Steroid regulation of human\n                    placental integrins: Suppression of \u03b12 integrin expression in cytotrophoblasts\n                    by glucocorticoids. Endocrinology 1999; 140: 3904-3908.\n                        https:\/\/doi.org\/10.1210\/endo.140.9.6999","DOI":"10.1210\/en.140.9.3904"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Lowin T, Straub RH, Neumann E, et al. Glucocorticoids increase\n                    alpha5 integrin expression and adhesion of synovial fibroblasts but inhibit ERK\n                    signaling, migration, and cartilage invasion. Arthritis Rheumatism 2009; 60:\n                    3623-3632. https:\/\/doi.org\/10.1002\/art.24985","DOI":"10.1002\/art.24985"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Wuebbles RD, Sarathy A, Kornegay JN, et al. Levels of \u03b17 integrin\n                    and laminin-\u03b12 are increased following prednisone treatment in the mdx mouse and\n                    GRMD dog models of duchenne muscular dystrophy. Dis Model Mech. 2013; 6:\n                    1175-1184. https:\/\/doi.org\/10.1242\/dmm.012211","DOI":"10.1242\/dmm.012211"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Bindreither D, Ecker S, Gschirr B, et al. The synthetic\n                    glucocorticoids prednisolone and dexamethasone regulate the same genes in acute\n                    lymphoblastic leukemia cells. BMC Genomics 2014; 15: 662.\n                        https:\/\/doi.org\/10.1186\/1471-2164-15-662","DOI":"10.1186\/1471-2164-15-662"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Takahashi K, Nguyen TT, Watanabe A, et al. Involvement of BCR:: ABL1\n                    in laminin adhesion of philadelphia chromosome-positive acute lymphoblastic\n                    leukemia through upregulation of integrin \u03b16. Cancer Rep. 2024; 7: e2034.\n                        https:\/\/doi.org\/10.1002\/cnr2.2034","DOI":"10.1002\/cnr2.2034"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Monta\u00f1o A, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, et al.\n                        ETV6\/RUNX1 fusion gene abrogation decreases the\n                    oncogenicity of tumour cells in a preclinical model of acute lymphoblastic\n                    leukaemia. Cells 2020; 9: 215.\n                    https:\/\/doi.org\/10.3390\/cells9010215","DOI":"10.3390\/cells9010215"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Collins K, Cardinali JL, Mnayer LO, et al. CD49f protein expression\n                    varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low\n                    in KMT2a-rearranged cases. Cytometry Part B: Clin Cytom. 2021;\n                    100: 243-248. https:\/\/doi.org\/10.1002\/cyto.b.21865","DOI":"10.1002\/cyto.b.21865"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Murphy JM, Rodriguez YA, Jeong K, et al. Targeting focal adhesion\n                    kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020; 52:\n                    877-886. https:\/\/doi.org\/10.1038\/s12276-020-0447-4","DOI":"10.1038\/s12276-020-0447-4"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Yang X, Chitalia SV, Matsuura S, et al. Integrins and their role in\n                    megakaryocyte development and function. Experiment Hematol. 2022; 106: 31-39.\n                        https:\/\/doi.org\/10.1016\/j.exphem.2021.11.007","DOI":"10.1016\/j.exphem.2021.11.007"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Tucker KL, Sage T, Stevens JM, et al. A dual role for\n                    integrin-linked kinase in platelets: Regulating integrin function and \u03b1-granule\n                    secretion. Blood 2008; 112: 4523-4531.\n                        https:\/\/doi.org\/10.1182\/blood-2008-03-148502","DOI":"10.1182\/blood-2008-03-148502"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Shalapour S, Hof J, Kirschner-Schwabe R, et al. High VLA-4\n                    expression is associated with adverse outcome and distinct gene expression\n                    changes in childhood B-cell precursor acute lymphoblastic leukemia at first\n                    relapse. Haematologica 2011; 96: 1627-1635.\n                        https:\/\/doi.org\/10.3324\/haematol.2011.047993","DOI":"10.3324\/haematol.2011.047993"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/50\/article-p1983.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/50\/article-p1983.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/50\/article-p1983.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:41:02Z","timestamp":1785494462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/50\/article-p1983.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":33,"journal-issue":{"issue":"50"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33419","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}